# AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors

> **NCT00372736** · PHASE1 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 27 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** AEG35156
- **DRUG:** docetaxel
- **GENETIC:** protein expression analysis
- **GENETIC:** reverse transcriptase-polymerase chain reaction
- **OTHER:** flow cytometry
- **OTHER:** immunoenzyme technique
- **OTHER:** immunohistochemistry staining method
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00372736
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07-27
- **Primary completion:** 2009-03-24
- **Final completion:** 2012-01-06
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2023-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00372736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00372736, "AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00372736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*